Gossamer Bio (GOSS) Competitors

$0.34 -0.01 (-4.11%)

Closing price 04:00 PM Eastern

Extended Trading

$0.34 +0.01 (+1.49%)

As of 06:46 PM Eastern

GOSS vs. BCYC, GLSI, SOPH, CABA, and SIGA

Should you be buying Gossamer Bio stock or one of its competitors? The main competitors of Gossamer Bio include Bicycle Therapeutics (BCYC), Greenwich LifeSciences (GLSI), SOPHiA GENETICS (SOPH), Cabaletta Bio (CABA), and Siga Technologies (SIGA). These companies are all part of the "pharmaceutical products" industry.

How does Gossamer Bio compare to Bicycle Therapeutics?

Bicycle Therapeutics (NASDAQ:BCYC) and Gossamer Bio (NASDAQ:GOSS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

: In the previous week, Gossamer Bio had 18 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 24 mentions for Gossamer Bio and 6 mentions for Bicycle Therapeutics. Gossamer Bio's average media sentiment score of 0.11 beat Bicycle Therapeutics' score of -0.27 indicating that Gossamer Bio is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Bicycle Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral
Gossamer Bio
0 Very Positive mention(s)
0 Positive mention(s)
24 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: Bicycle Therapeutics currently has a consensus target price of $14.00, indicating a potential upside of 185.71%. Gossamer Bio has a consensus target price of $5.43, indicating a potential upside of 1,515.65%. Given Gossamer Bio's higher possible upside, analysts clearly believe Gossamer Bio is more favorable than Bicycle Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bicycle Therapeutics
1 Sell rating(s)
3 Hold rating(s)

5 Buy rating(s)

0 Strong Buy rating(s)
2.44
Gossamer Bio
2 Sell rating(s)

4 Hold rating(s)

4 Buy rating(s)

0 Strong Buy rating(s)
2.20
: Gossamer Bio has lower revenue, but higher earnings than Bicycle Therapeutics. Bicycle Therapeutics is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Bicycle Therapeutics $63.50M 5.38 -$218.96M -$3.15 N/A
Gossamer Bio $48.47M 1.63 -$170.37M -$0.75 N/A
: Bicycle Therapeutics has a net margin of -344.95% compared to Gossamer Bio's net margin of -351.49%. Gossamer Bio's return on equity of 0.00% beat Bicycle Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Bicycle Therapeutics -344.95% -35.74% -29.54%
Gossamer Bio -351.49% N/A -75.50%
: Bicycle Therapeutics has a beta of 1.56, indicating that its share price is 56% more volatile than the S&P 500. Comparatively, Gossamer Bio has a beta of 2.15, indicating that its share price is 115% more volatile than the S&P 500.
: 86.2% of Bicycle Therapeutics shares are owned by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are owned by institutional investors. 22.9% of Bicycle Therapeutics shares are owned by insiders. Comparatively, 7.2% of Gossamer Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bicycle Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Gossamer Bio	0 Very Positive mention(s)	0 Positive mention(s)	24 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicycle Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
Gossamer Bio	2 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicycle Therapeutics	$63.50M	5.38	-$218.96M	-$3.15	N/A
Gossamer Bio	$48.47M	1.63	-$170.37M	-$0.75	N/A

Company	Net Margins	Return on Equity	Return on Assets
Bicycle Therapeutics	-344.95%	-35.74%	-29.54%
Gossamer Bio	-351.49%	N/A	-75.50%

Summary

Bicycle Therapeutics and Gossamer Bio tied by winning 8 of the 16 factors compared between the two stocks.

How does Gossamer Bio compare to Greenwich LifeSciences?

Greenwich LifeSciences (NASDAQ:GLSI) and Gossamer Bio (NASDAQ:GOSS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

: In the previous week, Gossamer Bio had 23 more articles in the media than Greenwich LifeSciences. MarketBeat recorded 24 mentions for Gossamer Bio and 1 mentions for Greenwich LifeSciences. Gossamer Bio's average media sentiment score of 0.11 beat Greenwich LifeSciences' score of 0.00 indicating that Gossamer Bio is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Greenwich LifeSciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Gossamer Bio
0 Very Positive mention(s)
0 Positive mention(s)
24 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: Greenwich LifeSciences currently has a consensus target price of $47.50, indicating a potential upside of 113.00%. Gossamer Bio has a consensus target price of $5.43, indicating a potential upside of 1,515.65%. Given Gossamer Bio's higher probable upside, analysts clearly believe Gossamer Bio is more favorable than Greenwich LifeSciences.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Greenwich LifeSciences
1 Sell rating(s)
0 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.33
Gossamer Bio
2 Sell rating(s)

4 Hold rating(s)

4 Buy rating(s)

0 Strong Buy rating(s)
2.20
: Greenwich LifeSciences has higher earnings, but lower revenue than Gossamer Bio. Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Greenwich LifeSciences N/A N/A -$15.79M -$1.46 N/A
Gossamer Bio $48.47M 1.63 -$170.37M -$0.75 N/A
: Greenwich LifeSciences has a net margin of 0.00% compared to Gossamer Bio's net margin of -351.49%. Gossamer Bio's return on equity of 0.00% beat Greenwich LifeSciences' return on equity.
Company Net Margins Return on Equity Return on Assets
Greenwich LifeSciences N/A -1,042.84% -565.43%
Gossamer Bio -351.49% N/A -75.50%
: Greenwich LifeSciences has a beta of 1.39, indicating that its stock price is 39% more volatile than the S&P 500. Comparatively, Gossamer Bio has a beta of 2.15, indicating that its stock price is 115% more volatile than the S&P 500.
: 4.2% of Greenwich LifeSciences shares are owned by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are owned by institutional investors. 51.5% of Greenwich LifeSciences shares are owned by insiders. Comparatively, 7.2% of Gossamer Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Greenwich LifeSciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Gossamer Bio	0 Very Positive mention(s)	0 Positive mention(s)	24 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Greenwich LifeSciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Gossamer Bio	2 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Greenwich LifeSciences	N/A	N/A	-$15.79M	-$1.46	N/A
Gossamer Bio	$48.47M	1.63	-$170.37M	-$0.75	N/A

Company	Net Margins	Return on Equity	Return on Assets
Greenwich LifeSciences	N/A	-1,042.84%	-565.43%
Gossamer Bio	-351.49%	N/A	-75.50%

Summary

Gossamer Bio beats Greenwich LifeSciences on 11 of the 15 factors compared between the two stocks.

How does Gossamer Bio compare to SOPHiA GENETICS?

Gossamer Bio (NASDAQ:GOSS) and SOPHiA GENETICS (NASDAQ:SOPH) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

: In the previous week, Gossamer Bio had 16 more articles in the media than SOPHiA GENETICS. MarketBeat recorded 24 mentions for Gossamer Bio and 8 mentions for SOPHiA GENETICS. SOPHiA GENETICS's average media sentiment score of 0.45 beat Gossamer Bio's score of 0.11 indicating that SOPHiA GENETICS is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Gossamer Bio
0 Very Positive mention(s)
0 Positive mention(s)
24 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
SOPHiA GENETICS
0 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
: 81.2% of Gossamer Bio shares are held by institutional investors. Comparatively, 31.6% of SOPHiA GENETICS shares are held by institutional investors. 7.2% of Gossamer Bio shares are held by company insiders. Comparatively, 4.9% of SOPHiA GENETICS shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
: SOPHiA GENETICS has higher revenue and earnings than Gossamer Bio. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Gossamer Bio $48.47M 1.63 -$170.37M -$0.75 N/A
SOPHiA GENETICS $77.27M 4.49 -$79M -$0.51 N/A
: Gossamer Bio presently has a consensus target price of $5.43, suggesting a potential upside of 1,515.65%. SOPHiA GENETICS has a consensus target price of $7.50, suggesting a potential upside of 47.93%. Given Gossamer Bio's higher probable upside, equities analysts clearly believe Gossamer Bio is more favorable than SOPHiA GENETICS.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gossamer Bio
2 Sell rating(s)
4 Hold rating(s)

4 Buy rating(s)

0 Strong Buy rating(s)
2.20
SOPHiA GENETICS
1 Sell rating(s)

0 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.33
: SOPHiA GENETICS has a net margin of -44.22% compared to Gossamer Bio's net margin of -351.49%. Gossamer Bio's return on equity of 0.00% beat SOPHiA GENETICS's return on equity.
Company Net Margins Return on Equity Return on Assets
Gossamer Bio -351.49% N/A -75.50%
SOPHiA GENETICS -44.22% -50.60% -21.00%
: Gossamer Bio has a beta of 2.15, indicating that its share price is 115% more volatile than the S&P 500. Comparatively, SOPHiA GENETICS has a beta of 1.01, indicating that its share price is 1% more volatile than the S&P 500.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gossamer Bio	0 Very Positive mention(s)	0 Positive mention(s)	24 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
SOPHiA GENETICS	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gossamer Bio	$48.47M	1.63	-$170.37M	-$0.75	N/A
SOPHiA GENETICS	$77.27M	4.49	-$79M	-$0.51	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gossamer Bio	2 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20
SOPHiA GENETICS	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Company	Net Margins	Return on Equity	Return on Assets
Gossamer Bio	-351.49%	N/A	-75.50%
SOPHiA GENETICS	-44.22%	-50.60%	-21.00%

Summary

Gossamer Bio and SOPHiA GENETICS tied by winning 8 of the 16 factors compared between the two stocks.

How does Gossamer Bio compare to Cabaletta Bio?

Gossamer Bio (NASDAQ:GOSS) and Cabaletta Bio (NASDAQ:CABA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

: In the previous week, Gossamer Bio had 17 more articles in the media than Cabaletta Bio. MarketBeat recorded 24 mentions for Gossamer Bio and 7 mentions for Cabaletta Bio. Cabaletta Bio's average media sentiment score of 0.47 beat Gossamer Bio's score of 0.11 indicating that Cabaletta Bio is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Gossamer Bio
0 Very Positive mention(s)
0 Positive mention(s)
24 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Cabaletta Bio
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
: 81.2% of Gossamer Bio shares are held by institutional investors. 7.2% of Gossamer Bio shares are held by company insiders. Comparatively, 11.3% of Cabaletta Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
: Cabaletta Bio has lower revenue, but higher earnings than Gossamer Bio. Cabaletta Bio is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Gossamer Bio $48.47M 1.63 -$170.37M -$0.75 N/A
Cabaletta Bio N/A N/A -$167.86M -$2.28 N/A
: Gossamer Bio presently has a consensus target price of $5.43, suggesting a potential upside of 1,515.65%. Cabaletta Bio has a consensus target price of $17.00, suggesting a potential upside of 309.64%. Given Gossamer Bio's higher probable upside, equities analysts clearly believe Gossamer Bio is more favorable than Cabaletta Bio.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gossamer Bio
2 Sell rating(s)
4 Hold rating(s)

4 Buy rating(s)

0 Strong Buy rating(s)
2.20
Cabaletta Bio
1 Sell rating(s)

0 Hold rating(s)

6 Buy rating(s)

0 Strong Buy rating(s)
2.71
: Cabaletta Bio has a net margin of 0.00% compared to Gossamer Bio's net margin of -351.49%. Gossamer Bio's return on equity of 0.00% beat Cabaletta Bio's return on equity.
Company Net Margins Return on Equity Return on Assets
Gossamer Bio -351.49% N/A -75.50%
Cabaletta Bio N/A -121.73% -90.19%
: Gossamer Bio has a beta of 2.15, indicating that its share price is 115% more volatile than the S&P 500. Comparatively, Cabaletta Bio has a beta of 3.18, indicating that its share price is 218% more volatile than the S&P 500.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gossamer Bio	0 Very Positive mention(s)	0 Positive mention(s)	24 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cabaletta Bio	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gossamer Bio	$48.47M	1.63	-$170.37M	-$0.75	N/A
Cabaletta Bio	N/A	N/A	-$167.86M	-$2.28	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gossamer Bio	2 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20
Cabaletta Bio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Company	Net Margins	Return on Equity	Return on Assets
Gossamer Bio	-351.49%	N/A	-75.50%
Cabaletta Bio	N/A	-121.73%	-90.19%

Summary

Gossamer Bio beats Cabaletta Bio on 8 of the 15 factors compared between the two stocks.

How does Gossamer Bio compare to Siga Technologies?

Gossamer Bio (NASDAQ:GOSS) and Siga Technologies (NASDAQ:SIGA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

: In the previous week, Gossamer Bio had 21 more articles in the media than Siga Technologies. MarketBeat recorded 24 mentions for Gossamer Bio and 3 mentions for Siga Technologies. Siga Technologies' average media sentiment score of 0.67 beat Gossamer Bio's score of 0.11 indicating that Siga Technologies is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Gossamer Bio
0 Very Positive mention(s)
0 Positive mention(s)
24 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Siga Technologies
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Siga Technologies has higher revenue and earnings than Gossamer Bio. Gossamer Bio is trading at a lower price-to-earnings ratio than Siga Technologies, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Gossamer Bio $48.47M 1.63 -$170.37M -$0.75 N/A
Siga Technologies $94.57M 3.52 $23.28M $0.31 14.97
: 81.2% of Gossamer Bio shares are held by institutional investors. Comparatively, 55.4% of Siga Technologies shares are held by institutional investors. 7.2% of Gossamer Bio shares are held by insiders. Comparatively, 2.0% of Siga Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
: Gossamer Bio presently has a consensus target price of $5.43, suggesting a potential upside of 1,515.65%. Given Gossamer Bio's stronger consensus rating and higher possible upside, equities research analysts clearly believe Gossamer Bio is more favorable than Siga Technologies.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gossamer Bio
2 Sell rating(s)
4 Hold rating(s)

4 Buy rating(s)

0 Strong Buy rating(s)
2.20
Siga Technologies
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
: Siga Technologies has a net margin of 24.61% compared to Gossamer Bio's net margin of -351.49%. Siga Technologies' return on equity of 11.25% beat Gossamer Bio's return on equity.
Company Net Margins Return on Equity Return on Assets
Gossamer Bio -351.49% N/A -75.50%
Siga Technologies 24.61% 11.25% 9.98%
: Gossamer Bio has a beta of 2.15, indicating that its stock price is 115% more volatile than the S&P 500. Comparatively, Siga Technologies has a beta of 0.93, indicating that its stock price is 7% less volatile than the S&P 500.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gossamer Bio	0 Very Positive mention(s)	0 Positive mention(s)	24 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Siga Technologies	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gossamer Bio	$48.47M	1.63	-$170.37M	-$0.75	N/A
Siga Technologies	$94.57M	3.52	$23.28M	$0.31	14.97

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gossamer Bio	2 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20
Siga Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Net Margins	Return on Equity	Return on Assets
Gossamer Bio	-351.49%	N/A	-75.50%
Siga Technologies	24.61%	11.25%	9.98%

Summary

Siga Technologies beats Gossamer Bio on 9 of the 16 factors compared between the two stocks.

Get Gossamer Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GOSS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GOSS vs. The Competition

Export

Metric	Gossamer Bio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$78.86M	$3.39B	$6.25B	$11.87B
Dividend Yield	N/A	2.20%	2.73%	5.21%
P/E Ratio	-0.45	38.85	29.04	28.47
Price / Sales	1.63	155.53	476.61	60.94
Price / Cash	N/A	57.88	27.62	36.52
Price / Book	-0.63	7.03	9.67	6.67
Net Income	-$170.37M	$23.62M	$3.55B	$332.53M
7 Day Performance	-2.58%	3.67%	1.70%	2.01%
1 Month Performance	-9.19%	7.16%	5.62%	9.20%
1 Year Performance	-73.12%	67.03%	34.42%	39.59%

Gossamer Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GOSS Gossamer Bio	2.5197 of 5 stars	$0.34 -4.1%	$5.43 +1,515.6%	N/A	$78.86M	$48.47M	N/A	180	Trending News Upcoming Earnings
BCYC Bicycle Therapeutics	3.0496 of 5 stars	$4.77 -1.4%	$14.38 +201.4%	N/A	$337.38M	$72.86M	N/A	240	Earnings Report Analyst Downgrade
GLSI Greenwich LifeSciences	1.0012 of 5 stars	$23.99 -0.9%	$47.50 +98.0%	N/A	$335.42M	N/A	N/A	3
SOPH SOPHiA GENETICS	3.2095 of 5 stars	$4.86 +0.2%	$7.50 +54.3%	N/A	$332.16M	$77.27M	N/A	520	Earnings Report
CABA Cabaletta Bio	2.2628 of 5 stars	$2.91 -1.4%	$17.00 +484.2%	N/A	$328.41M	N/A	N/A	50	News Coverage Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GOSS) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Gossamer Bio (GOSS) Competitors

GOSS vs. BCYC, GLSI, SOPH, CABA, and SIGA

How does Gossamer Bio compare to Bicycle Therapeutics?

Summary

How does Gossamer Bio compare to Greenwich LifeSciences?

Summary

How does Gossamer Bio compare to SOPHiA GENETICS?

Summary

How does Gossamer Bio compare to Cabaletta Bio?

Summary

How does Gossamer Bio compare to Siga Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GOSS vs. The Competition

Gossamer Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Gossamer Bio (GOSS) Competitors

GOSS vs. BCYC, GLSI, SOPH, CABA, and SIGA

How does Gossamer Bio compare to Bicycle Therapeutics?

Summary

How does Gossamer Bio compare to Greenwich LifeSciences?

Summary

How does Gossamer Bio compare to SOPHiA GENETICS?

Summary

How does Gossamer Bio compare to Cabaletta Bio?

Summary

How does Gossamer Bio compare to Siga Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GOSS vs. The Competition

Gossamer Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools